A review published in The Nurse Practitioner on Apr. 27 examines the expanding clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), highlighting both their growing promise and the need for careful monitoring and equitable access.
The review is important as GLP-1RAs are increasingly used not only for type 2 diabetes and obesity but also show potential benefits in cardiovascular, renal, hepatic, and neurocognitive health. With more patients seeking these medications due to media coverage of rapid weight loss effects, clinicians face new challenges in ensuring safe prescribing practices.
Researchers say that nurse practitioners must balance enthusiasm with vigilance by recognizing side effects and adjusting treatment based on patient-specific risks. "They should recognize side effects and patient-specific risks while adjusting treatment as weight and metabolic markers such as glycated hemoglobin (HbA1c) and lipid profiles evolve," the review says. The article outlines that GLP-1RAs improve glycemic control, lower blood pressure, support weight reduction, and provide cardioprotective benefits. It also notes that major guidelines recommend these agents as first-line therapy for patients with type 2 diabetes who have or are at high risk for atherosclerotic cardiovascular disease, chronic kidney disease (CKD), or obesity.
While most patients tolerate GLP-1RAs well, gastrointestinal symptoms like nausea or vomiting can occur early in treatment but often subside over time. The review recommends strategies such as gradual dose escalation to minimize discontinuation rates. Serious adverse events remain rare but include pancreatitis or gallbladder issues; therefore clinicians should exercise caution in certain high-risk groups.
Access remains a concern due to high costs, variable insurance coverage, and risks associated with non-approved compounded products. Nurse practitioners play an important role by advocating for patients' needs while promoting informed discussions about safe use.
The authors conclude that although evidence supports broader roles for GLP-1 therapies beyond diabetes management—including cardiovascular protection—clinicians must continue to tailor treatments to individual patient profiles while monitoring outcomes closely.
